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Impact of Mitral Valve Annuloplasty
Combined With Revascularization in Patients
With Functional Ischemic Mitral Regurgitation
Tomislav Mihaljevic, MD,* Buu-Khanh Lam, MD,* Jeevanantham Rajeswaran, MSC,†
Masami Takagaki, MD,* Michael S. Lauer, MD,‡ A. Marc Gillinov, MD,*
Eugene H. Blackstone, MD,*† Bruce W. Lytle, MD*
Cleveland, Ohio
Objectives The aim of this work was to determine whether mitral valve (MV) annuloplasty benefits patients with moderate/se-
vere (3/4) functional ischemic mitral regurgitation (MR) who undergo coronary artery bypass grafting (CABG).
Background Mitral regurgitation is a strong predictor of poor outcomes in patients with ischemic cardiomyopathy; whether
correcting it at the time of CABG improves outcomes is less certain.
Methods From 1991 to 2003, 390 patients with 3/4 ischemic MR had CABG with (n  290) or without (n  100) MV
annuloplasty. Groups were propensity-matched using demographics, extent of coronary disease, regional wall
motion, and quantitative electrocardiography. Survival, echocardiographic severity of MR, and New York Heart
Association (NYHA) functional class were compared.
Results One-, 5-, and 10-year survival was 88%, 75%, and 47% after CABG alone and 92%, 74%, and 39% after CABG 
MV annuloplasty (p  0.6). Mortality was increased in patients with severe lateral wall motion abnormalities
(p  0.05), ST-segment elevation in lateral leads (p  0.004), and higher QRS voltage sum (p  0.0001). Pa-
tients undergoing CABG alone were more likely to have 3/4 postoperative MR than those undergoing CABG
 MV annuloplasty (48% vs. 12% at 1 year, p  0.0001). The NYHA functional class substantially improved in
both groups (p  0.001) and remained improved; at 5 years, 23% of patients having CABG  mitral annulo-
plasty and 25% having CABG alone were in NYHA functional class III/IV.
Conclusions Although CABG  MV annuloplasty reduces postoperative MR and improves early symptoms compared with
CABG alone, it does not improve long-term functional status or survival in patients with severe functional isch-
emic MR. The MV annuloplasty in this setting, without addressing fundamental ventricular pathology, is insuffi-
cient to improve long-term clinical outcomes. (J Am Coll Cardiol 2007;49:2191–201) © 2007 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.02.043a
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tunctional ischemic mitral regurgitation (MR) is strongly
ssociated with poor outcomes in patients with advanced
oronary artery disease (1). However, whether its correction
mproves outcomes is unclear.
See page 2202
Ischemic MR is not caused by gross intrinsic disease of
he valve, but by left ventricular (LV) remodeling, dilation,
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nc. and AtriCure, Inc. This paper was presented at the 55th Annual Meeting of the
merican College of Cardiology, Atlanta, Georgia, March 11 to 14, 2006.e
Manuscript received September 8, 2006; revised manuscript received February 5,
007, accepted February 5, 2007.nd dysfunction leading to geometric reconfiguration of the
itroventricular apparatus, including papillary muscle dis-
lacement and annular dilation. Mitral valve (MV) leaflets
ecome tethered, with failure of anterior-posterior leaflet
oaptation, resulting in symmetric or asymmetric regur-
itation. Surgical treatment options include coronary
rtery bypass grafting (CABG) alone or with concomi-
ant MV annuloplasty or replacement. Currently, the
ost common technique to restore valve competence is
lacing an undersized annuloplasty ring to reduce mitral
nnulus size.
Whether or not MV annuloplasty improves outcomes
ver and above CABG alone is debated, however (2).
herefore, in the absence of evidence-based on randomized
rials, this clinical study has 2 objectives: 1) to determine the
fficacy of MV annuloplasty in patients who are comparable
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based on extent of coronary ar-
tery disease, regional wall motion
abnormalities, severity of MR,
quantitative echocardiograms,
and clinical characteristics; and
2) to discover clinically useful
features and predictors of out-
comes that might identify which
patients, if any, are more likely to
benefit from adding MV annulo-
plasty to their revascularization
procedure.
Methods
Patients. From 1991 to 2003 at
the Cleveland Clinic, 100 pa-
tients with chronic, severe (3 or
4) functional ischemic MR,
previous myocardial infarction,
and ejection fraction 45% by
reoperative transthoracic echocardiography (TTE) under-
ent CABG alone (CABG group), and 290 underwent
ABG with concomitant MV annuloplasty (CABGMV
nnuloplasty group). Ischemic MR was defined as MR
esulting from myocardial infarction, not from intrinsic MV
isease (Carpentier types I and IIIb). Patients’ clinical
ecords were reviewed to verify that their MR was caused by
schemic heart disease and myocardial infarction and did not
ust coexist with them. Patients who underwent other
oncomitant procedures (including LV restoration), those
ith ruptured papillary muscle, and 49 patients with atrial
brillation, atrial flutter, or a pacemaker were excluded
because these rhythm disturbances adversely affected the
uantitative echocardiogram analysis).
urgical management. The decision to perform MV sur-
ery was made by the surgeon and cardiologist on the basis
f clinical presentation and findings at echocardiography
nd cardiac catheterization. All operations were performed
n cardiopulmonary bypass using antegrade and retrograde
old blood cardioplegia. Coronary artery bypass grafting was
erformed in standard fashion, using a single-clamp tech-
ique. In patients undergoing MV annuloplasty, a left atrial
pproach was used and the valve inspected to confirm the
iagnosis. Size of annuloplasty ring was smaller than the
urface area of the anterior MV leaflet to ensure annulus
downsizing” (3).
Annuloplasty technique varied over the course of the
tudy. They included partial flexible annuloplasty band
n  207, 71%; Cosgrove-Edwards Annuloplasty System,
dwards Lifesciences, Irvine, California), rigid annuloplasty
ing (n  63, 22%; Carpentier-Edwards Classic Annulo-
lasty Ring, Edwards Lifesciences), and posterior suture
lication with autologous pericardium or Peri-Guard graft
Abbreviations
and Acronyms
CABG  coronary artery
bypass grafting
CL  confidence limits
IRB  institutional review
board
LV  left ventricular
MR  mitral regurgitation
MRI  magnetic resonance
imaging
MV  mitral valve
NYHA  New York Heart
Association
PET  positron emission
tomography
TEE  transesophageal
echocardiogram
TTE  transthoracic
echocardiogramn 20, 6.9%; Baxter Healthcare Corp., Deerfield, Illinois). yPerioperative inotropic therapy was guided by the hemo-
ynamic condition of the patient. Routine postoperative use
f dopamine or other inotropic agents was not practiced.
ata. Preoperative and operative variables were retrieved
rom the cardiovascular information registry, augmented by
uantitative echocardiogram (4) and echocardiography da-
abases. All databases were approved for research by the
nstitutional review board, with patient consent waived.
Recent work has highlighted the value of quantitatively
ssessed echocardiogram measures of LV mass, depolariza-
ion, and repolarization as potentially powerful predictors of
isk in a variety of cardiovascular conditions (5,6). Because
chocardiograms are inexpensive, routinely obtained, and
elatively easy to describe quantitatively, we extended these
bservations to our study to refine propensity matching.
chocardiogram analyses included heart rhythm, right and
eft bundle branch block patterns, and locations of prior
-wave myocardial infarctions. Using specialized software
Magellan Echocardiogram Research Work Station, Gen-
ral Electric Marquette Medical Imaging, Milwaukee, Wis-
onsin), computerized measures were made of P-wave
uration; PR, QRS, and QT intervals; Cornell and
okolow-Lyon voltages as measures of LV mass; and
T-segment changes. ST-segment slope was calculated as
he difference of ST-segment deviation at the J-point and at
he end of the ST-segment.
Preoperative ventriculograms and TTE were used to
ssess global LV function, graded regional wall motion,
everity of MR, and regurgitant jet direction (Appendix). A
ostoperative TTE was performed routinely before hos-
ital discharge and during follow-up at the discretion of
he referring physician. None of the echocardiographic
ata in this report is based on intraoperative transesoph-
geal studies (TEE).
Myocardial viability was assessed in only a small number
f patients by magnetic resonance imaging (MRI) (33
atients) or positron emission tomography (PET) (76 pa-
ients). Only 21 patients (3 MRI, 18 PET) from matched
ohorts had undergone myocardial viability assessment pre-
peratively. There was no statistically significant difference
n presence of ischemia versus scar in any of the LV wall
egments between groups. These data were insufficient to
tudy the association of myocardial viability with postoper-
tive outcomes.
utcomes. Outcomes assessed were all-cause time-related
ortality, TTE grade of postoperative MR, and postoper-
tive New York Heart Association (NYHA) functional
tatus. Patients undergoing CABG alone were systemati-
ally followed by questionnaire and telephone interview
very 5 years for vital status, functional status, and cardiac
vents. Those undergoing CABGMV annuloplasty were
ollowed similarly at 2-year intervals. All follow-up was
erformed under institutional review board-approved pro-
ocols, with patient consent.
Median follow-up was 5 years for CABG alone and 4
ears for CABGMV annuloplasty; 10% of survivors were
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June 5, 2007:2191–201 CABG  MV Annuloplasty for Functional Ischemic MRollowed more than 11 and 9 years, respectively. We
onsidered estimates of outcome reliable to 10 years.
Postoperative TTEs were available for a subset of 247
atients (63%) with 518 assessments of MR. These studies
ere concentrated early postoperatively, with median time
o assessment of 5.3 months after CABG alone and 1.1
onths after CABG  MV annuloplasty.
The NYHA functional class was derived algorithmically
rom a grid of symptoms and functional limitations self-
eported by the patient. A subgroup of 257 patients (66%)
ad 403 postoperative functional status assessments at a
edian of 5 and 2.3 years for CABG alone and CABG 
V annuloplasty, respectively.
ata analysis. FAIR COMPARISON. Data analysis first ad-
ressed dissimilarities between CABG alone and CABG 
V annuloplasty patients (Tables 1 and 2) so that compar-
son of outcomes would be fair and based on more extensive
isk adjustment than has heretofore been done.
Multivariable logistic regression was used to identify a
arsimonious set of preoperative factors (Appendix) associ-
ted with performing CABG alone versus CABG  MV
nnuloplasty. Bagging was used for variable selection (7),
ith automated analysis of 500 bootstrap samples and a
value for retention of 0.05. Frequency of occurrence of
ndividual factors or clusters of highly correlated factors in
hese analyses was counted (aggregation step), and factors
ppearing in 50% or more of the analyses were considered
eliably statistically significant at a value of p  0.05.
To this parsimonious model were added nonsignificant
ariables representing groups of patient, coronary disease,
egional wall motion, and echocardiogram variables that
ight be related to unrecorded selection factors (saturated
ropensity model) (8,9). Using this saturated model, a
ropensity score was calculated for each patient. Both
ABG alone and CABG  MV annuloplasty cases were
hen matched on propensity score alone. This yielded 54
ell-matched pairs (Tables 1 and 2).
URVIVAL. Survival was estimated nonparametrically by the
aplan-Meier method and parametrically by a multiphase
azard model (10). Two hazard phases were resolved, early
nd late, and because of this, proportional hazards modeling
ould have been inappropriate. Therefore, multivariable
nalyses were performed in the multiphase hazard function
omain simultaneously for each hazard phase using vari-
bles in (Appendix), with treatment group (CABG alone)
nd propensity score forced into each (11). Otherwise,
ariable selection was by bagging, as described under “Fair
omparison.”
OSTOPERATIVE MR. Time-related change in postoperative
R among propensity-matched patients was analyzed by
ongitudinal ordinal logistic regression for repeated mea-
ures (PROC GENMOD, SAS Institute Inc., Cary, North
arolina). Because of low frequency, grades 3 and 4
ere combined. Interval from operation to echocardio-
raphic assessment, CABG alone versus CABG  MV (nnuloplasty groups, and interaction between interval and
roup were included in the comparison model to assess
ifferences in rates of MR evolution.
OSTOPERATIVE FUNCTIONAL STATUS. Time-related
hange in NYHA functional class among propensity-
atched patients was analyzed using longitudinal ordinal
ogistic regression for repeated measurements, as described
nder “Postoperative MR.” Because of low frequency,
YHA functional classes III and IV were combined.
ENEFIT OF MV ANNULOPLASTY. Possible benefit of MV
nnuloplasty in reducing MR and improving functional
lass was assessed by examining overlap of confidence limits
CLs) of propensity-matched longitudinal estimates. Search
or any survival benefit of MV annuloplasty was made by:
) multivariable propensity-adjusted analysis for each haz-
rd phase; 2) superimposing propensity-matched hazard
unctions for death; and 3) calculating the difference in
xpected 7-year survival with CABG alone versus CABG
V annuloplasty. The latter was done by solving the
ultivariable equation for death twice for each patient, first
y treatment received and then by treatment not received.
hese two 7-year estimates were subtracted and the differ-
nce examined by quintiles. This analysis suggested that
atients with prolonged myocardial ischemic time benefited
ost from CABG alone. This time, however, is highly
orrelated with receiving MV annuloplasty and so was
urposely not used in any analyses. Nevertheless, we devel-
ped another model of mortality that included ischemic
imes, carefully examining its possible interaction with
reatment received.
resentation. Categorical data are summarized by fre-
uencies and percentages, with comparisons made using the
hi-square test, except as noted. Continuous variables are
ummarized as means  SD and as equivalent 15th, 50th
median), and 85th percentiles when data were skewed.
omparisons were made using the Wilcoxon rank sum
onparametric test. All analyses were performed using SAS
tatistical software (version 9.1, SAS Institute Inc.). For
onsistency, uncertainty is expressed by CLs equivalent
o 1 standard error (68%).
esults
perative results. In propensity-matched patients, those
ndergoing CABG  MV annuloplasty had longer cardio-
ulmonary bypass times (137  42 min vs. 107  38 min,
 0.0001) and myocardial ischemic times (97  24 min
s. 74  28 min, p  0.0001) than those undergoing
ABG alone, as expected. Reasons for not performing MV
nnuloplasty included downgrading of MR by intraopera-
ive TEE (58%), MR not considered clinically significant by
urgeon (11%), MR improved after CABG (8%), MR not
ddressed because of patient’s hemodynamic instability
5%), and reasons not noted by surgeon (18%).
Characteristics of Patients Undergoing CABG Alone Versus CABG  Mitral Valve Annuloplasty—Categorical Variables
Table 1 Characteristics of Patients Undergoing CABG Alone Versus CABG  Mitral Valve Annuloplasty—Categorical Variables
Unmatched Patients Propensity-Matched Patients
Characteristic n*
CABG Alone
(n  100)
n (%) n*
CABG  MV
Annuloplasty (n  290)
n (%) p Value n*
CABG Alone
(54 Pairs)
n (%) n*
CABG  MV
Annuloplasty (54 Pairs)
n (%) p Value
Demography
Men 100 54 (54) 290 199 (69) 0.008 54 32 (59) 54 37 (69) 0.3
Symptoms and history
NYHA functional class 100 290 0.0005 54 54 0.9
I 16 (16) 22 (7.6) 9 (17) 7 (13)
II 34 (34) 122 (42) 18 (33) 20 (37)
III 22 (22) 103 (35) 14 (26) 14 (26)
IV 28 (28) 43 (15) 13 (24)
Mitral regurgitation
Grade 100 290 0.0001 54 54 0.5
3 85 (85) 150 (52) 41 (76) 44 (81)
4 15 (15) 140 (48) 13 (24) 10 (18)
Left ventricle
Dysfunction 92 232 0.02 52 52 0.8
None 11 (12) 12 (5.2) 3 (5.8) 4 (7.7)
Mild 19 (21) 27 (12) 11 (21) 8 (15)
Moderate 30 (33) 85 (37) 16 (31) 15 (29)
Severe 32 (34) 108 (46) 22 (42) 25 (48)
Coronary artery disease
Location of stenoses† 54 54
Left main 100 22 (22) 290 70 (24) 0.7 13 (24) 14 (26) 0.8
LAD system 100 92 (92) 290 258 (89) 0.4 48 (89) 50 (93) 0.5
LCx system 100 89 (89) 289 233 (81) 0.06 48 (89) 47 (87) 0.8
RCA system 100 91 (91) 290 266 (92) 0.8 49 (91) 48 (89) 0.8
ECG variables 93 261
Myocardial infarction 48 45
Anterolateral 2 (2.2) 10 (3.8) 0.4 1 (2.1) 0 (0) 0.3
Anterior 5 (5.4) 17 (6.5) 0.7 4 (8.3) 7 (16) 0.3
Anteroseptal 5 (5.4) 17 (6.5) 0.7 3 (6.2) 6 (13) 0.2
Inferior 32 (34) 89 (34) 0.9 18 (38) 17 (38) 0.9
Lateral 3 (3.2) 7 (2.7) 0.8 2 (4.2) 1 (2.2) 0.6
Posterior 1 (1.1) 4 (1.5) 0.7 0 (0) 1 (2.2) 0.3
Septal 9 (10) 13 (5.0) 0.1 3 (6.2) 2 (4.4) 0.7
Continued on next page
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Continued
Table 1 Continued
Unmatched Patients Propensity-Matched Patients
Characteristic n*
CABG Alone
(n  100)
n (%) n*
CABG  MV
Annuloplasty (n  290)
n (%) p Value n*
CABG Alone
(54 Pairs)
n (%) n*
CABG  MV
Annuloplasty (54 Pairs)
n (%) p Value
Noncardiac comorbidity
Smoking 100 58 (58) 288 192 (67) 0.1 54 33 (61) 54 35 (65) 0.7
Peripheral arterial disease 100 44 (44) 290 139 (48) 0.5 54 24 (44) 54 26 (48) 0.7
Hypertension 95 65 (68) 272 194 (71) 0.6 50 35 (70) 48 34 (71) 0.9
Treated diabetes 98 40 (41) 282 100 (35) 0.3 54 23 (42) 53 17 (32) 0.3
Renal disease 100 9 (9) 290 31 (11) 0.6 54 4 (7.4) 54 6 (11) 0.5
Procedure
Annuloplasty type — — 290 — — — 54 —
Cosgrove-Edwards — 207 (71) 32 (59)
Carpentier-Edwards — 63 (22) 14 (26)
Peri-Guard — 20 (6.9) 8 (15)
Number of bypass grafts 100 290 0.1 54 54 0.7
1 5 (5) 37 (13) 3 (5.6) 4 (7.4)
2 12 (12) 57 (20) 7 (13) 12 (22)
3 44 (44) 99 (34) 26 (48) 20 (37)
4 30 (30) 75 (26) 15 (28) 13 (24)
5 7 (7) 18 (6.2) 2 (3.7) 3 (5.6)
6 2 (2) 4 (1.4) 1 (1.8) 2 (3.7)
Number of ITA grafts 100 290 0.8 54 54 0.8
0 38 (38) 109 (37) 21 (39) 19 (35)
1 60 (60) 171 (59) 31 (57) 32 (59)
2 2 (2) 10 (3.5) 2 (3.7) 3 (5.6)
Postoperative management
Mechanical circulatory support 100 9 (9) 290 21 (7.2) 0.6 54 6 (11) 54 5 (9.3) 0.8
*Data available; †50% stenosis.
CABG  coronary artery bypass grafting; ECG  electrocardiographic; ITA  internal thoracic artery; LAD  left anterior descending coronary artery; LCx  left circumflex artery; MV  mitral valve; NYHA  New York Heart Association; RCA  right coronary artery.
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Characteristics of Patients Undergoing CABG Alone Versus CABG  Mitral Valve Annuloplasty—Continuous Variables
Table 2 Characteristics of Patients Undergoing CABG Alone Versus CABG  Mitral Valve Annuloplasty—Continuous Variables
Unmatched Patients Propensity-Matched Patients
Characteristic n*
CABG Alone (n  100)
Mean  SD or Percentiles† n*
CABG  MV Annuloplasty (n  290)
Mean  SD or Percentiles† p Value n*
CABG Alone (54 Pairs)
n (%) n*
CABG  MV Annuloplasty
(54 Pairs) n (%) p Value
Demography
Age (yrs) 100 68 8.7 290 65 9.4 0.02 54 66 9.2 54 66 9.6 0.7
ECG variables 93 261 48 45
Ventricular variables
QRS sum (mV) 12,742 (9,208, 16,432) 13,021 (9,634, 17,180) 0.7 13,086 (9,435, 16,421) 12,328 (9,698, 15,338) 0.2
QRS duration (ms) 104 (88, 140) 108 (92, 140) 0.05 104 (88, 128) 108 (92, 133) 0.6
Ischemia variables (mV)
ST-segment slope: lead V5 4.5 (49, 30) 0 (49, 58) 0.05 5 (49, 47) 10 (60, 24) 0.7
ST-segment end: lead V5 42 (152, 14) 35 (127, 52) 0.1 54 (136, 24) 42 (160, 12) 0.9
Support variables (min)
Myocardial ischemic time 73 74 26 275 96 26 0.0001 43 74 28 50 97 24 0.0001
CPB time 74 107 36 277 132 38 0.0001 43 107 38 51 137 42 0.0001
Management (days) 290 54 54
Hospital length of stay 100 10 (6, 17) 12 (6, 23) 0.02 9 (6, 17) 10 (6, 21) 0.4
ICU length of stay 99 2 (1, 5) 2 (1, 6) 0.003 1.5 (1, 4.1) 2 (1, 5) 0.1
Postoperative length of stay 100 7 (5, 12) 8 (6, 16) 0.0002 7 (5, 12) 8 (6, 19) 0.02
*Data available; †50th (15th, 85th) percentiles.
CPB  cardiopulmonary bypass; ICU  intensive care unit; other abbreviations as in Table 1.
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June 5, 2007:2191–201 CABG  MV Annuloplasty for Functional Ischemic MRMore than 60% of patients in each group received at least
internal thoracic artery graft. Hospital mortality was 7.4%
CL 3.9% to 13%) after CABG alone and 3.7% (CL 1.3 to
.4%) after CABG  MV annuloplasty (p  0.7).
urvival. In both unadjusted comparisons (Fig. 1A) and
hose of propensity-matched patients (Fig. 1B), survival
fter CABG  MV annuloplasty was similar to that after
ABG alone (p 0.6). In matched pairs, it was 97% versus
4% at 30 days, 92% versus 88% at 1 year, 74% versus 75%
t 5 years, and 39% versus 47% at 10 years. Risk factors
ssociated with early death included severe lateral wall
otion abnormality, renal insufficiency, lower hematocrit,
nd earlier date of operation; CABG  MV annuloplasty
ersus CABG alone was not a risk factor (p  0.3)
Figure 1 Survival Ater CABG Either Alone or With Concomitant
MV Annuloplasty for Functional Ischemic MR
Symbols represent deaths positioned according to the Kaplan-Meier estimator,
vertical bars are 68% confidence limits, and numbers in parentheses are
patients still alive. Solid lines are parametric estimates enclosed within 68%
confidence limits. (A) Unadjusted survival, based on 37 deaths after coronary
artery bypass grafting (CABG) alone and 92 after CABG  mitral valve (MV)
annuloplasty. (B) Propensity-matched survival, based on 19 deaths after CABG
alone and 19 after CABG  MV annuloplasty. MR  mitral regurgitation.Table 3). Risk factors associated with late death included
elder age, insulin-treated diabetes, renal insufficiency,
igher QRS voltage sum, and larger positive and negative
alues of ST-segment slope in the fifth precordial echocar-
iogram lead (Fig. E1 in the Appendix), but not CABG 
V annuloplasty versus CABG alone (p  0.2).
ostoperative MR. Patients undergoing CABG  MV
nnuloplasty experienced less severe postoperative MR com-
ared with those undergoing CABG alone (p 0.0001). After
ABG alone, early presence and recurrence of MR was
articularly pronounced, with the proportion of patients
aving no MR decreasing from 51% to 8% within the first
ew weeks of surgery (Figs. E2A and E2B in the Appendix).
ecurrence was considerably slower after CABG  MV
nnuloplasty; the proportion of patients with no MR
eclined from 86% immediately postoperatively to 43% 6
onths after surgery, while the proportion with 3/4
R increased from 1% to 9%. The latter continued to
ncrease gradually thereafter (Fig. 2).
ostoperative NYHA functional class. Substantial im-
rovement occurred pre- to postoperatively in functional
tatus in both groups (Figs. E3A and E3B in the Appendix).
omparison of temporal trends in propensity-matched
roups showed that although the CABG  MV annulo-
lasty group appeared to have a slightly lower percentage of
atients with severe symptoms (NYHA functional class III
nd IV) at 5 years, this difference was not statistically
ignificant (23% for CABGMV annuloplasty vs. 25% for
ABG alone, p  0.3). Over time, the percentage of
ncremental Risk Factors for Death
Table 3 Incremental Risk Factors for Death
Factor Estimate  SE p Value
Reliability
(%)*
Early phase
CABG alone 0.82 0.84 0.3
Propensity score† 1.2 0.98 0.2
Severe lateral wall-motion
abnormality‡
1.03 0.56 0.06 72
Renal disease 1.9 0.50 0.0001 83
Lower hematocrit§ 0.53 0.10 0.0001 46
Earlier date of operation 0.67 0.26 0.01 72
Late phase
CABG alone 0.38 0.32 0.2
Propensity score† 0.32 0.50 0.5
ST-segment slope: lead V5 86
Lower slope¶ 0.13 0.042 0.002
Higher slope# 20 6.6 0.003
Lower slope** 0.29 0.103 0.004
Higher QRS voltage sum†† 0.36 0.084 0.0001 64
Older‡‡ 2.3 1.1 0.04 43
Previous cardiac operation 0.61 0.22 0.007 54
Insulin-treated diabetes 0.66 0.26 0.01 62
Higher BUN 0.024 0.0066 0.0004 85
Percent of occurrences in bootstrap models; †probability of undergoing CABG alone; ‡lateral wall
otion grades 0, 1, 2, 3, 4 versus 5, 6, a binary variable; §(40/hematocrit), inverse transformation;
Ln (interval from January 1, 1991, to date of operation), logarithmic transformation; ¶ST-segment
lope: lead 5/3, scaled; #Exp(ST-segment slope: lead 5/500), exponential transformation; **(Ab-
olute value of ST-segment slope: lead 5/150)3, cubic transformation; ††Exp (QRS/sum/13,000),
xponential transformation; ‡‡(50/age), inverse transformation.
BUN  blood urea nitrogen; CABG  coronary artery bypass grafting.
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nnuloplasty group remained constant, but the percentage
n the CABG alone group increased, although graphically,
onfidence intervals overlap (Fig. 3).
enefit of MV annuloplasty. The most apparent value of
V annuloplasty was immediate elimination of 3 and 4
R, which was only partially mitigated by CABG alone.
atients experienced similar 7- to 8-year symptomatic
enefit from both procedures (Fig. E3 in the Appendix).
he early hazard function for death was more prolonged
fter CABG alone (Fig. 4), but in multivariable analysis, no
arly survival benefit of adding MV annuloplasty to CABG
Figure 2 Proportion of Patients in MR Grades 3 or 4
Proportion of patients in mitral regurgitation (MR) grades 3 or 4 after opera-
tion. Horizontal axis is on a logarithmic scale that greatly expands times
shortly after operation to better depict rapid change in the course of MR.
Abbreviations as in Figure 1.
Figure 3 Temporal Trend of NYHA Functional
Classes III or IV for Propensity-Matched Patients
Solid lines represent mean effect for various functional classes. Symbols rep-
resent data grouped within time frame without regard to repeated assessment
to provide a crude verification of model fit. NYHA  New York Heart Associa-
tion; other abbreviations as in Figure 1.tas evident (Tables 3 and E1 [in the Appendix]). Analysis
f predicted 7-year survival differences indicated that older
atients with more comorbidities who had a longer period
f myocardial ischemia (Fig. E4 in the Appendix) had
omewhat worse survival after CABG  MV annuloplasty
han after CABG alone; however, after adjusting for aortic
lamp time, nearly all differences were 15%, and 60%
ere 10%.
iscussion
ey findings. Key findings were that: 1) CABG  MV
nnuloplasty almost completely eliminated MR, but this is
nly partially durable; 2) CABG with or without MV
nnuloplasty substantially improved symptoms; 3) addition
f MV annuloplasty to CABG had no evident survival
enefit; 4) survival of patients with ischemic cardiomyopa-
Figure 4 Hazard Function (Instantaneous Risk) for Death After
CABG Alone or With Concomitant MV Annuloplasty
Solid lines are parametric estimates and dashed lines are their 68% confi-
dence limits. (A) Unadjusted hazard. (B) Hazard in propensity-matched pairs.
Abbreviations as in Figure 1.hy and MR was primarily influenced by the presence of
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ime of operation.
Ischemic cardiomyopathy with associated functional MR
s a leading cause of heart failure, affecting more than 5
illion Americans. Limited treatment options for these
atients have prompted aggressive surgical and interven-
ional approaches to correct functional MR (2), with the
ope of reversing ventricular remodeling, ameliorating
ymptoms of heart failure, and improving survival (3).
Optimal treatment of important ischemic MR at the
ime of CABG remains controversial, however. Some
eport that CABG alone results in improved ejection
raction, reduced MR, and better survival (12,13). Others
ndicate that CABG alone leaves many patients with
linically significant residual MR, which may be subop-
imal therapy (14 –16). These latter reports have resulted
n wide use of MV annuloplasty at time of CABG, with
nticipated improvement in symptoms and late survival
17). Nevertheless, a survival advantage of MV annulo-
lasty has not been demonstrated in this or other studies,
espite reduced MR (18). These conflicting results likely
eflect the heterogeneous nature of the disease, nonstand-
rdized surgical treatments, and the absence of random-
zed study design. In addition, some reports mix ischemic
ardiomyopathy with idiopathic dilated cardiomyopathy,
aking interpretation of results of MV annuloplasty
ifficult (19).
HOICE OF TREATMENT FOR FUNCTIONAL ISCHEMIC MR.
ost surgeons base their choice of procedure for functional
schemic MR on patients’ clinical status (severity of symptoms,
isk profile) and MR severity, with great institutional and
ndividual variance. Preoperative TTE is more likely than
ntraoperative TEE to reflect the true degree of MR, because
R is often artificially downgraded by altered hemodynamics
n anesthetized patients. We, therefore, matched patients by
everity of MR on preoperative TTE. Choice of procedure was
ased on the surgeon’s clinical assessment, with a number of
atients undergoing CABG alone due to “downgrading” of
R by intraoperative TEE. It is important to emphasize that
downgrading of MR” did not change the underlying severity
f MR, but only the perception of it.
Although assessment of myocardial viability provides
mportant clinical information, it was not used as a guide in
reating patients in our study, nor has it been in any major
tudy on the same subject.
V ANNULOPLASTY AND MR. Reduction of MR by MV
nnuloplasty using partial or complete annuloplasty rings is
ccomplished by reducing the septal-lateral diameter of the
nnulus, with resulting improved leaflet coaptation (3).
revious reports document 17% to 29% prevalence of
ecurrent MR early or late postoperatively (20,21). Annu-
oplasty technique in those studies was not uniform. The
emporal pattern of developing postoperative MR was
imilar for rigid or flexible annuloplasty bands, but substan-
ially worse for Peri-Guard (Baxter Healthcare Corp.) snnuloplasty (22). Mitral valve annuloplasty in our study
as usually performed using a partial flexible annuloplasty
ing, our preferred current surgical technique. Mitral valve
nnuloplasty can also be performed with partial rigid rings
r complete rings; however, differences in ring design have
ot yet translated into demonstrably improved outcomes
19). Recurrence of postoperative MR has also been asso-
iated with higher grade of preoperative MR and more
evere LV dysfunction. In our study, these factors were
ontrolled for by preoperative matching.
Although prevalence of important (3 to 4) postoper-
tive MR (9% at 6 months, 20% at 5 years) in our study
ompares favorably with previous reports, these proportions
emain substantial. This likely is the consequence of LV
emodeling with an ongoing increase in papillary muscle
isplacement (22).
URVIVAL. Patients with chronic ischemic MR are at mark-
dly higher risk of heart failure than those with competent
alves, and this risk is proportional to MR severity (1,23).
he risk persists even after successful percutaneous or
urgical revascularization, with resulting decreased postpro-
edural survival (15,24). This striking, well-documented
ssociation of ischemic MR and survival has resulted in the
ypothesis that eliminating MR at revascularization im-
roves outcomes. Unfortunately, we and others have failed
o demonstrate improved survival of these patients with
ddition of MV annuloplasty. The reasons are unclear, but
ay indicate that functional ischemic MR is only a mani-
estation of advanced infarction-induced ventricular remod-
ling and that survival of these patients is primarily dictated
y extent of their ischemic heart disease (25). This is
ubstantiated by decreased survival associated with MV
eplacement that permanently eliminates MR but does not
ddress ventricular remodeling (and may contribute to it)
26). Presence of myocardial ischemia and hypertrophy were
ound to be predictors of early and late risk in our study,
urther supporting this hypothesis.
Alternatively, this finding may be the result of inability of
nnuloplasty to completely and permanently eliminate MR.
lthough annuloplasty reduces MR in all patients in the
hort term, there is gradual recurrence in the long term. It
emains to be seen whether improved annuloplasty ring
esign will result in long-term durable elimination of MR
nd improved functional status and survival (19).
YMPTOMS. Coronary artery bypass grafting with or with-
ut MV annuloplasty provides substantial and lasting symp-
om relief. However, there was a suggestion of progressive
eturn of severe (NYHA functional class III/IV) symptoms
ate after CABG alone. This may indicate that worsening of
eart failure symptoms is associated with residual or recur-
ent MR.
ENEFIT OF MV ANNULOPLASTY. Adding MV annuloplasty
o CABG eliminates MR in the short term, improves
ymptoms—as does CABG alone—but has no demonstra-
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CABG MV Annuloplasty for Functional Ischemic MR June 5, 2007:2191–201le survival benefit. Nevertheless, prolonged myocardial
schemic time, particularly in older ill patients, increases the
arly risk of death.
tudy limitations. This is a single-institution, nonran-
omized clinical study conducted over a protracted period
uring which documented and undocumented differences
n decision-making and surgical management occurred.
e attempted to compensate for lack of randomization
y more extensive propensity matching than has been
one previously (27). This resulted in 2 groups of patients
ell matched on demographic characteristics, extent of
oronary artery disease, LV wall motion abnormalities,
everity of MR, and quantitative echocardiogram abnor-
alities. Although randomized trials represent the gold
tandard in clinical research, this approach may be
ifficult because of the heterogeneity of ischemic cardio-
yopathy after myocardial infarction of varying extent,
ocalization, and transmurality; variable LV remodel-
ng in response; and variable remaining coronary artery
isease.
We do not routinely obtain preoperative echocardiograms
n patients’ underlying CABG, but do so on patients with
history of heart failure. Thus, some patients with impor-
ant but unrecognized MR may have been missed. How-
ver, we believe the sample of patients is representative of
he prevalence of severe ischemic MR in patients with
oronary artery disease undergoing CABG. This is the
argest study of such patients.
The groups were analyzed by treatment received, because
e could not reliably ascertain treatment intended.
Nonsystematic echocardiographic follow-up is an impor-
ant limitation. Postoperative echocardiograms were ob-
ained at the discretion of treating cardiologists and were
ikely indicated by the clinical condition of the patient. This
ntroduces the potential risk of overrepresentation of pa-
ients with severe postoperative MR. However, two-thirds
f echocardiograms were obtained within the first year of
peration, during which time it appears that most changes
n MR grade occurred.
The question of whether recurrent MR directly affects
urvival is not possible to answer at present because both are
utcomes of surgical intervention, one longitudinal and the
ther an event; therefore, their possible interdependent
elationship with surgical technique awaits further develop-
ent of relevant statistical methodology.
linical implications. All these findings indicate that
yocardial factors, rather than MR, are the primary deter-
inants of outcome in patients with ischemic cardiomyop-
thy and MR. Any correction of MR, surgical or percuta-
eous, confined to the level of the annulus will likely result
n only temporary reduction in MR, although possibly more
apid recovery from the operative intervention. If the benefit
f MV annuloplasty, without addressing myocardial remod-
ling, occurs primarily early after CABG, one might predict
hat the benefit of percutaneous MV annuloplasty may also
e limited to the period of early recovery after percutaneous
1oronary intervention. Neither may improve long-term
urvival.
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